The House Energy and Commerce Subcommittee on Oversight and Investigations today held the second part of a hearing on the rising cost of insulin, which featured witnesses from the nation’s three insulin manufacturers as well as three pharmacy benefit managers.
 
“It appears that there is limited competition and little incentive to keep prices at a level that patients can afford,” Committee Chairman Frank Pallone, D-N.J., said in opening remarks. “And perhaps there are incentives in place to keep raising prices. As a result, we are left with a drug that has been available for nearly 100 years, and yet the price tripled and then doubled in just the last couple decades. Clearly, something is not right here.”
 
During the first part of the hearing last week, diabetes care witnesses described the impact of rising insulin prices on patients.

Related News Articles

Headline
The House Energy and Commerce Committee today approved legislation to address surprise medical bills and Medicaid disproportionate share hospital cuts.
Headline
The Trump administration today withdrew a proposed rule that would eliminate the rebate safe harbor for pharmacy benefit managers under the federal anti-…
Headline
A federal judge yesterday struck down a Centers for Medicare…
Headline
Drug makers this week increased list prices for at least 104 different drugs, dosages or package sizes, with the average price increase 13.1%, according to an…
Headline
The Senate Judiciary Committee today passed four bills aimed at lowering prescription drug costs and increasing competition.
Headline
The Senate Committee on Health, Education, Labor and Pensions today voted 20-3 to pass the Lower Health Care Costs Act (S.1895) – bipartisan legislation…